Adhesys Medical Gmbh

Boehringer Ingelheim International Gmbh

Medical Adhesive Revolution Gmbh

Bayer Schering Pharma Ag

Covestro Deutschland Ag

Bayer Materialscience Ag

Bayer Pharma Aktiengesellschaft

Covestro Intellectual Property Gmbh & Co. Kg

Bayer Intellectual Property Gmbh

Heike Heckroth

Christoph Eggert

Adrian Tersteegen

Martin Hendrix

Lars Bärfacker

Dagmar Karthaus

Hartmut Nefzger

Marja Van Kampen

Frank-Thorsten Hafner

Franz-Josef Van Der Staay

Christina Erb

Sebastian Dörr

Burkhard Köhler

Jörg Hofmann

Klaus Lorenz

Dieter Lang

Karl-Heinz Schlemmer

Christian Wamprecht

Jens-Kerim Ergüden

Johannes-Peter Stasch

Thomas Schenke

Reinhard Halpaap

Peter Kolkhof

Edward P Browne

Rainer Weber

Frank Richter

Rolf Grosser

Joachim Mittendorf

Achim Feurer

Elke Stahl

Raimund Kast

Siegfried R Waldvogel

Ingo Flamme

Heike Gielen-Haertwig

Hartmut Schirok

Ulrich Ebert

Marcus Bauser

Hans-Otto Werling

Santiago Figueroa Perez

Alexander Kuhl

Klaus Münter

Samir Bennabi

Jan Schönberger

Robrecht Froyman

Christoph Herwig

Bettina Beyreuther

Ian Teasdale

Heimo Ehmke

Kristine Fraatz

Sebastian Herold

Jan Suetterlin

Jean Mark Gnoth

Hans-Robert Hehnen

Lars Baerfacker

Donya Kamravamanesh

Christine Erb

Jens Ergüden

Yan-Hong Liu

Nicole Mahler

Oliver Plavcan

Vinh Trieu

Marta Feroci

Gianpiero Forte

Achille Inesi

Isabella Chiarotto

Edward Browne

Christoph Ulbricht

Oliver Brueggemann

Jan-Patrick Bachmann

Susanne Kimeswenger

Florian Hartmann

The present invention relates to an aqueous composition comprising cells of at least one strain of a halophilic microorganism, and alkali sulfate in a concentration of at least 30 g/l based on the total volume of the aqueous composition. The present invention further relates to a method for treating a waste water, comprising obtaining or providing a waste water, contacting said waste water with cells of at least one strain of a halophilic microorganism, and thereby generating an aqueous composition comprising alkali sulfate in a concentration of at least 30 g/l, and incubating said aqueous composition under conditions which allow for the treatment of the waste water.

Recycling of alkali sulfate rich waste water by biological pre-treatment with an extreme halophilic organism

The present invention relates to a method for reducing the aniline content of hypersaline wastewater, said method comprising the steps of (a) providing a composition A comprising hypersaline wastewater and aniline, and (b) contacting composition A with cells of at least one halophilic microbial strain, thereby generating a composition B comprising said composition A and cells of said at least one halophilic microbial strain. The present invention further concerns a method for the production of chlorine and sodium hydroxide. Further encompassed by the present invention is a composition comprising hypersaline wastewater, aniline, and cells of at least one halophilic microbial strain.

Biodegradation of aniline from hypersaline environments using halophilic microorganisms

The present invention relates to a method that includes providing a formulation having an isocyanate-functional prepolymer and a curing component comprising an amino-functional aspartic ester of the general formula (I) applying the formulation to a cell tissue; and curing the formulation such that the loss of blood (haemostatic) or tissue fluids is staunched or leaks in cell tissues are sealed.

Medical adhesives for stopping heavy bleeding and sealing leakages

Polyurea systems comprising: (a) an amino-functional aspartic ester of the general formula (I) wherein X represents an n-valent organic radical derived from a corresponding n-functional primary amine X(NH), Rand Reach independently represent an organic radical having no Zerevitinov active hydrogens and n represents an integer of at least 2; and (b) an isocyanate functional prepolymer having a residual monomer content of less than 1% by weight, the prepolymer prepared by reacting: (b1) an aliphatic isocyante; and (b2) a polyol component having a number average molecular weight of &#x2265;400 g/mol and an average OH functionality of 2 to 6, wherein the polyol component comprises one or more constituents selected from the group consisting of polyester polyols, polyester-polyether polyols and mixtures thereof; processes for making the same; postoperative adhesions barriers prepared therewith and dispensing systems for such polyurea systems.

Polyurea systems, processes for preparing the same and use thereof for postoperative adhesion barriers

The present invention relates to a process for producing a hydroxy amino polymer comprising the steps:

Hydroxy amino polymer and use thereof in polyurea/polyurethane tissue adhesives

The present invention relates to a polyurea system, the use of such a polyurea system for sealing, linking, gluing, or covering of cellular tissue, and a dosing system having two chambers for a polyurea system such as this. The polyurea system comprises as components: A) an isocyanate-functioning prepolymer, which can be derived by reacting aliphatic isocyanates with polyoles, and B) an amino-functioning ester of aspartic acid. According to the invention, water and/or tertiary amine is added to the system, in order to increase the reacting speed of the prepolymer with the amino-functioning ester of aspartic acid while decreasing the setting time at the same time.

Polyurea-based fabric glue

The present invention relates to an isocyanate functional prepolymer that can be achieved through The invention additionally relates to a process for producing this isocyanate functional prepolymer, a tissue adhesive system containing such an isocyanate functional prepolymer and a dispensing system having at least two chambers and this type of tissue adhesive system.

Isocyanate-functional prepolymer for a biologically degradable fabric adhesive

The invention relates to a polyurea system comprising as component A) isocyanate-functional prepolymers which can be obtained by reacting aliphatic isocyanates A1) with polyols A2) that can have a number-average molecular weight of =400 g/mol and an average OH functionality of 2 to 6 in particular; and as component B) amino-functional aspartic acid esters of the general formula (I) in which X is an organic group containing a secondary amino function, R1, R2 are the same or different organic groups that do not have Zerewitinoff-active hydrogen, and n is a whole number of at least 2, in particular for sealing, bonding, gluing, or covering cell tissue. The invention also relates to a metering system for the polyurea system according to the invention.

Tissue adhesive based on nitrogen-modified aspartates

The present invention relates to a polyurea system comprising as component A) isocyanate-functional prepolymers obtainable by reaction of aliphatic isocyanates A1) with polyols A2), which in particular can have a number-average molecular weight of &#x2267;400 g/mol and a mean OH functionality of from 2 to 6, as component B) an amino-functional compound of the general formula (I) in which X is an organic radical containing a secondary amino function, Y is an organic radical that contains a tertiary amino group and does not contain Zerewitinoff-active hydrogen, Ris a CH&#x2014;COORradical in which Ris an organic radical that does not contain Zerewitinoff-active hydrogen, a linear or branched C1- to C4-alkyl radical, a cyclopentyl radical, a cyclohexyl radical or H, Ris an organic radical that does not contain Zerewitinoff-active hydrogen, a is 1 or 2, b is 1 or 2, and a+b=2 or 3, for stemming the escape of blood, and to a metering system for the polyurea system according to the invention.

Medical adhesive for stemming bleeding

Growing community of inventors

Odenthal, Germany

Heike Heckroth